Skip to main content

MRI Biomarkers: Data Analysis and Tool Generation


This funding program will support studies to develop reproducible diagnostic, prognostic, and monitoring magnetic resonance imaging (MRI) biomarkers.

Advances in MRI offer the opportunity to improve Parkinson’s disease (PD) diagnosis and monitoring. But these measures still show significant overlap between PD and control volunteers. And patterns elucidated from group comparisons cannot yet be applied to individual patients for definitive diagnosis.

This program prioritizes three goals:

  1. Modeling and analytics: leveraging existing imaging data to develop novel analyses methodology to (i) enable early detection of PD, (ii) identify imaging patterns unique to phenotypic subtypes of PD, and (iii) track disease progression and the efficacy of therapeutic intervention
  2. Novel imaging sequences or post-processing techniques: developing and validating novel MRI sequences and novel post-processing techniques that provide insights into the mechanisms underlying PD
  3. Tool and platform development: developing generalizable and easily deployable tools and platforms to enhance biomarker identification, disease classification and clinical decision making

Prospective data collection is only permitted for studies that utilize novel MRI sequences.

Researchers from public and private institutions are encouraged to apply and to collaborate.

Informational Webinar 
We will host a webinar on August 24, 2021, at 12 p.m. ET to clarify and explain the goals of our funding opportunities and answer applicant questions. The webinar will be available to view on-demand after the live airdate. Register today.

Application Process 
1. Download the RFA overview and application template 
2. Log in or create an account in the grant application portal.
3. Submit your completed application. 

Email with questions.


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.